

Trevor R Norman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8571460/publications.pdf>

Version: 2024-02-01

202
papers

5,066
citations

87888

38
h-index

123424

61
g-index

205
all docs

205
docs citations

205
times ranked

4444
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Melatonin Suppression by Light is Intensity Dependent. <i>Journal of Pineal Research</i> , 1989, 6, 149-156.	7.4	389
2	Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 41-49.	4.5	317
3	A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2009, 31, 848-859.	1.3	156
4	Behavioural studies of spatial working memory dysfunction in schizophrenia: A quantitative literature review. <i>Psychiatry Research</i> , 2007, 150, 111-121.	3.3	142
5	Acute increases in night-time plasma melatonin levels following a period of meditation. <i>Biological Psychology</i> , 2000, 53, 69-78.	2.2	116
6	Melatonin Sensitivity to Dim White Light in Affective Disorders. <i>Neuropsychopharmacology</i> , 1999, 21, 408-413.	5.4	106
7	Overnight human plasma melatonin, Cortisol, prolactin, TSH, under conditions of normal sleep, sleep deprivation, and sleep recovery. <i>Journal of Pineal Research</i> , 1996, 20, 7-14.	7.4	96
8	Selective Effects of Acute Serotonin and Catecholamine Depletion on Memory in Healthy Women. <i>Journal of Psychopharmacology</i> , 2004, 18, 32-40.	4.0	92
9	Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience. <i>Australian and New Zealand Journal of Psychiatry</i> , 1989, 23, 369-372.	2.3	88
10	Effect of Sodium Valproate on Nocturnal Melatonin Sensitivity to Light in Healthy Volunteers. <i>Neuropsychopharmacology</i> , 2005, 30, 1400-1404.	5.4	82
11	Impairments of Spatial Working Memory and Attention Following Acute Psychosocial Stress. <i>Stress and Health</i> , 2015, 31, 115-123.	2.6	80
12	Neuropsychological study of underweight and "recovered" anorexia nervosa compared with bulimia nervosa and normal controls. <i>International Journal of Eating Disorders</i> , 2007, 40, 613-621.	4.0	75
13	Serotonin in Panic Disorder. <i>International Clinical Psychopharmacology</i> , 1989, 4, 1-6.	1.7	71
14	Melatonin Rhythm in Human Plasma Saliva. <i>Journal of Pineal Research</i> , 1987, 4, 177-183.	7.4	70
15	Platelet monoamine oxidase: Low activity in cigarette smokers. <i>Psychiatry Research</i> , 1987, 20, 199-205.	3.3	69
16	Quantal melatonin suppression by exposure to low intensity light in man. <i>Life Sciences</i> , 1989, 45, 327-332.	4.3	69
17	The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. <i>Psychoneuroendocrinology</i> , 2006, 31, 867-875.	2.7	68
18	Dopamine D1 receptor binding in the striatum of patients with obsessive-compulsive disorder. <i>Journal of Affective Disorders</i> , 2009, 114, 321-326.	4.1	68

#	ARTICLE	IF	CITATIONS
19	Breastfeeding and the use of psychotropic medication: a review. <i>Journal of Affective Disorders</i> , 1990, 19, 197-206.	4.1	65
20	Alterations to Plasma Melatonin and Cortisol After Evening Alprazolam Administration in Humans. <i>Chronobiology International</i> , 1993, 10, 205-213.	2.0	63
21	Low doses of lithium carbonate reduce melatonin light sensitivity in healthy volunteers. <i>International Journal of Neuropsychopharmacology</i> , 2005, 8, 255-259.	2.1	61
22	Platelet monoamine oxidase activity and cigarette smoking. <i>Journal of Affective Disorders</i> , 1982, 4, 73-77.	4.1	59
23	Combining pindolol and paroxetine in an animal model of chronic antidepressant action—can early onset of action be detected?. <i>European Journal of Pharmacology</i> , 1998, 352, 23-28.	3.5	57
24	Third-Generation Antidepressants. <i>CNS Drugs</i> , 2001, 15, 941-954.	5.9	57
25	Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans. <i>Biological Psychiatry</i> , 1988, 24, 108-112.	1.3	52
26	Onset of the Effects of the 5-HT _{1A} Antagonist, WAY-100635, Alone, and in Combination With Paroxetine, on Olfactory Bulbectomy and 8-OH-DPAT—Induced Changes in the Rat. <i>Pharmacology Biochemistry and Behavior</i> , 1999, 63, 333-338.	2.9	51
27	Olanzapine excretion in human breast milk: estimation of infant exposure. <i>International Journal of Neuropsychopharmacology</i> , 2002, 5, 243-7.	2.1	51
28	A controlled study of a specific MAO A reversible inhibitor (R011-1163) and amitriptyline in depressive illness. <i>Journal of Affective Disorders</i> , 1985, 8, 29-35.	4.1	45
29	Human melatonin response to light at different times of the night. <i>Psychoneuroendocrinology</i> , 1989, 14, 187-193.	2.7	45
30	The treatment of depression with different formulations of venlafaxine: a comparative analysis. <i>Human Psychopharmacology</i> , 2004, 19, 9-16.	1.5	45
31	Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 2000, 748, 439-443.	1.7	44
32	In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. <i>Human Psychopharmacology</i> , 2001, 16, 541-544.	1.5	44
33	Plasma Melatonin Concentrations in Depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 1986, 20, 381-383.	2.3	42
34	The emerging role of pharmacogenetics: implications for clinical psychiatry. <i>Australian and New Zealand Journal of Psychiatry</i> , 2004, 38, 483-489.	2.3	42
35	Platelet serotonin uptake in panic disorder. <i>Journal of Affective Disorders</i> , 1986, 11, 69-72.	4.1	41
36	Serotonergic and Dopaminergic Systems in Anorexia Nervosa: A Role for Atypical Antipsychotics?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2005, 39, 146-153.	2.3	40

#	ARTICLE	IF	CITATIONS
37	Stability of cognitive impairment in chronic schizophrenia over brief and intermediate reâ€test intervals. <i>Human Psychopharmacology</i> , 2009, 24, 113-121.	1.5	40
38	Agomelatine for depression: expanding the horizons?. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 647-656.	1.8	40
39	The biological basis of anxiety. <i>Journal of Affective Disorders</i> , 1985, 9, 271-284.	4.1	38
40	Low platelet monoamine oxidase and sensation seeking in males: an established relationship?. <i>Acta Psychiatrica Scandinavica</i> , 1987, 75, 86-90.	4.5	37
41	The Evaluation of Depression in Inpatients with HIV Disease. <i>Australian and New Zealand Journal of Psychiatry</i> , 1999, 33, 344-352.	2.3	36
42	Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers. <i>Human Psychopharmacology</i> , 2003, 18, 619-625.	1.5	36
43	Analysis of tricyclic antidepressant drugs in plasma and serum by chromatographic techniques. <i>Biomedical Applications</i> , 1985, 340, 173-197.	1.7	34
44	Spatial working memory and problem solving in schizophrenia: The effect of symptom stabilization with atypical antipsychotic medication. <i>Psychiatry Research</i> , 2008, 160, 316-326.	3.3	34
45	Cigarette smoking and plasma nortriptyline levels. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 21, 453-456.	4.7	33
46	The effect of gender on the melatonin suppression by light: a dose response relationship. <i>Journal of Neural Transmission</i> , 2000, 107, 271-279.	2.8	32
47	Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5â€HT_{1A} receptor agonist. <i>Human Psychopharmacology</i> , 2009, 24, 437-446.	1.5	32
48	Dopamine D1 receptor binding in the anterior cingulate cortex of patients with obsessiveâ€compulsive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2010, 183, 85-88.	1.8	31
49	The effect of venlafaxine treatment on the behavioural and neurochemical changes in the olfactory bulbectomised rat. <i>Psychopharmacology</i> , 1998, 136, 394-401.	3.1	30
50	Modulation of plasma melatonin concentrations by changes in posture. <i>Journal of Pineal Research</i> , 1998, 24, 219-223.	7.4	29
51	An open-label study of quetiapine in anorexia nervosa. <i>Human Psychopharmacology</i> , 2007, 22, 223-230.	1.5	29
52	Abnormal dose-response melatonin suppression by light in bipolar type I patients compared with healthy adult subjects. <i>Acta Neuropsychiatrica</i> , 2009, 21, 246-255.	2.1	29
53	Pharmacological Treatment of Panic Disorder. <i>International Clinical Psychopharmacology</i> , 1986, 1, 3-16.	1.7	27
54	The effect of dim light on suppression of nocturnal melatonin in healthy women and men. <i>Journal of Neural Transmission</i> , 1997, 104, 643-648.	2.8	27

#	ARTICLE	IF	CITATIONS
55	Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Human Psychopharmacology, 2000, 15, 161-264.	1.5	27
56	Pindolol Augmentation of Antidepressants: A Review and Rationale. Australian and New Zealand Journal of Psychiatry, 2000, 34, 71-79.	2.3	27
57	Melatonin, cortisol and prolactin response to acute nocturnal light exposure in healthy volunteers. Psychoneuroendocrinology, 1992, 17, 243-248.	2.7	26
58	New Formulations of Existing Antidepressants. CNS Drugs, 2004, 18, 505-520.	5.9	26
59	Pharmacokinetics of N-desmethyldiazepam after a single oral dose of clorazepate: The effect of smoking. European Journal of Clinical Pharmacology, 1981, 21, 229-233.	1.9	24
60	Prolactin response to dl-fenfluramine in panic disorder. Psychoneuroendocrinology, 1993, 18, 337-342.	2.7	24
61	A Multicentre Double Blind Trial of Fluoxetine versus Amitriptyline in the Treatment of Depressive Illness. Australian and New Zealand Journal of Psychiatry, 1993, 27, 49-55.	2.3	24
62	The effect of atenolol, a β_1 -adrenergic antagonist, on nocturnal plasma melatonin secretion: Evidence for a dose-response relationship in humans. Journal of Pineal Research, 1997, 23, 131-135.	7.4	24
63	A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. International Clinical Psychopharmacology, 2006, 21, 87-92.	1.7	24
64	Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT _{2c} antagonist, S32006. European Journal of Pharmacology, 2012, 674, 27-32.	3.5	24
65	Neurochemical effects of the enantiomers of mirtazapine in normal rats. European Journal of Pharmacology, 1998, 356, 121-126.	3.5	23
66	Metabolism and pharmacokinetics of dothiepin.. British Journal of Clinical Pharmacology, 1981, 12, 405-409.	2.4	22
67	Negative symptoms, depression and parkinsonian symptoms in chronic, hospitalised schizophrenic patients. Journal of Affective Disorders, 1998, 48, 163-169.	4.1	22
68	Determination of nefazodone and its pharmacologically active metabolites in human blood plasma and breast milk by high-performance liquid chromatography. Biomedical Applications, 1999, 730, 249-255.	1.7	22
69	Antidepressants and Breast-Feeding. Paediatric Drugs, 2000, 2, 183-192.	3.1	22
70	Effects of serotonin and catecholamine depletion on interleukin-6 activation and mood in human volunteers. Human Psychopharmacology, 2002, 17, 293-297.	1.5	20
71	Plasma and breast milk concentrations of dothiepin and nortriaden in lactating women. Human Psychopharmacology, 1993, 8, 29-33.	1.5	19
72	Long-term drug treatment of panic disorder. Journal of Psychiatric Research, 1993, 27, 111-125.	3.1	19

#	ARTICLE	IF	CITATIONS
73	Fast-Acting Antidepressants. <i>CNS Drugs</i> , 1994, 2, 120-131.	5.9	19
74	3. Assessment of anxiety and depression in primary care. <i>Medical Journal of Australia</i> , 1997, 167, 328-333.	1.7	19
75	Discontinuation Syndromes with Selective Serotonin Reuptake Inhibitors. <i>CNS Drugs</i> , 1999, 12, 171-177.	5.9	19
76	Brain serotonin depletion by lesions of the median raphe nucleus enhances the psychotomimetic action of phencyclidine, but not dizocipine (MK-801), in rats. <i>Brain Research</i> , 2005, 1049, 217-226.	2.2	19
77	Quetiapine augmentation in depressed patients with partial response to antidepressants. <i>Human Psychopharmacology</i> , 2008, 23, 653-660.	1.5	19
78	A pharmacokinetic study of mianserin. <i>European Journal of Clinical Pharmacology</i> , 1982, 21, 517-520.	1.9	18
79	Measurement of moclobamide, a new monoamine oxidase inhibitor, by gas chromatography with nitrogen-selective detection. <i>Biomedical Applications</i> , 1983, 278, 429-433.	1.7	18
80	The pineal hormone melatonin in panic disorder. <i>Journal of Affective Disorders</i> , 1987, 12, 203-206.	4.1	18
81	Platelet serotonin uptake and 3H-imipramine binding in panic disorder. <i>Journal of Affective Disorders</i> , 1989, 17, 77-81.	4.1	18
82	Emerging treatments for major depression. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 203-213.	2.8	17
83	Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience. <i>Australian and New Zealand Journal of Psychiatry</i> , 1989, 23, 369-372.	2.3	17
84	Serotonergic function in panic disorder: Endocrine responses to d-Fenfluramine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1994, 18, 329-337.	4.8	16
85	Treatment of Anxiety During Pregnancy. <i>Drug Safety</i> , 1999, 20, 171-186.	3.2	16
86	Blunted growth hormone response to clonidine in post-traumatic stress disorder. <i>Psychoneuroendocrinology</i> , 2004, 29, 269-278.	2.7	16
87	An investigation of the effect of tacrine and physostigmine on spatial working memory deficits in the olfactory bulbectomised rat. <i>Behavioural Brain Research</i> , 2004, 153, 481-486.	2.2	16
88	The Impact of a Changed Environment on Arousal Levels of Patients in a Secure Extended Rehabilitation Facility. <i>Australasian Psychiatry</i> , 2009, 17, 207-211.	0.7	16
89	New Pharmacological Approaches to the Management of Depression: From Theory to Clinical Practice. <i>Australian and New Zealand Journal of Psychiatry</i> , 1992, 26, 73-81.	2.3	15
90	Aggressive behaviour and platelet 3H-paroxetine binding in schizophrenia. <i>Schizophrenia Research</i> , 1997, 23, 61-67.	2.0	15

#	ARTICLE	IF	CITATIONS
91	PHARMACOKINETICS AND PLASMA LEVELS OF ANTIDEPRESSANTS IN THE ELDERLY. Medical Journal of Australia, 1979, 1, 273-274.	1.7	15
92	Simultaneous measurement of dothiepin and its major metabolites in plasma and whole blood by gas chromatography-mass fragmentography. Biomedical Applications, 1981, 222, 399-408.	1.7	14
93	Platelet 3H-rauwolscine binding in patients with panic attacks. Psychiatry Research, 1987, 22, 43-48.	3.3	14
94	Fenfluramine Augmentation of Clomipramine Treatment of Obsessive Compulsive Disorder. Australian and New Zealand Journal of Psychiatry, 1991, 25, 412-414.	2.3	14
95	Sertraline Analysis in the Plasma of Breast-Fed Infants. Australian and New Zealand Journal of Psychiatry, 2001, 35, 545-546.	2.3	14
96	Psychotherapeutic Drugs. Drugs, 1980, 20, 485-493.	10.9	13
97	Determination of tiapride in plasma by high-performance liquid chromatography. Biomedical Applications, 1986, 375, 197-201.	1.7	13
98	A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders. Drug Safety, 1995, 12, 46-54.	3.2	13
99	Successful treatment of serotonin syndrome with chlorpromazine. Medical Journal of Australia, 1996, 165, 345-346.	1.7	13
100	Platelet paroxetine binding in post-traumatic stress disorder. Psychiatry Research, 1998, 77, 1-7.	3.3	13
101	Continuation treatment of major depressive disorder: is there a case for duloxetine?. Drug Design, Development and Therapy, 2010, 4, 19.	4.3	13
102	Melatonin sensitivity to light in monozygotic twins discordant for bipolar I disorder. Australian and New Zealand Journal of Psychiatry, 2005, 39, 947-947.	2.3	13
103	Determination of therapeutic levels of butriptyline in plasma by gas-liquid chromatography. Journal of Chromatography A, 1977, 134, 524-528.	3.7	12
104	The pharmacokinetics of mianserin in elderly depressed patients. Psychiatry Research, 1983, 8, 281-287.	3.3	12
105	Platelet serotonin uptake in panic disorder patients: A replication study. Psychiatry Research, 1989, 30, 63-68.	3.3	12
106	Blunted prolactin response to ?-fenfluramine in post-stroke major depression. Journal of Affective Disorders, 2003, 76, 273-278.	4.1	12
107	5-HT _{2A} Agonists: A Novel Therapy for Functional Neurological Disorders?. International Journal of Neuropsychopharmacology, 2017, 20, 422-427.	2.1	12
108	Platelet [3H]paroxetine binding in panic disorder. Journal of Affective Disorders, 1995, 33, 117-122.	4.1	11

#	ARTICLE	IF	CITATIONS
109	Nocturnal plasma melatonin concentrations in healthy volunteers: Effect of single doses of d-fenfluramine, paroxetine, and ipsapirone. <i>Journal of Pineal Research</i> , 1996, 21, 55-58.	7.4	11
110	5. Benzodiazepines in anxiety disorders: managing therapeutics and dependence. <i>Medical Journal of Australia</i> , 1997, 167, 490-495.	1.7	11
111	The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light. <i>International Clinical Psychopharmacology</i> , 1999, 14, 189-192.	1.7	11
112	Prolactin response to d-fenfluramine in combat-related post-traumatic stress disorder. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 291-298.	2.1	11
113	Attenuation of benzodiazepine withdrawal anxiety in the rat by serotonin antagonists. <i>Behavioural Brain Research</i> , 2005, 161, 286-290.	2.2	11
114	Prospects for the Treatment of Depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 394-401.	2.3	11
115	Duloxetine in the treatment of generalized anxiety disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 4, 1169.	2.2	11
116	Psychosis after withdrawal of steroid therapy. <i>Medical Journal of Australia</i> , 1983, 2, 350-351.	1.7	11
117	Viloxazine plasma concentrations and clinical response. <i>Journal of Affective Disorders</i> , 1980, 2, 157-164.	4.1	10
118	Antidepressant therapy: benefits and risks in perspective. <i>Acta Psychiatrica Scandinavica</i> , 1985, 72, 43-47.	4.5	10
119	Platelet Serotonin Uptake in Panic Disorder: Comparison with Normal Controls and the Effect of Treatment. <i>Australian and New Zealand Journal of Psychiatry</i> , 1988, 22, 390-395.	2.3	10
120	A Case of Moclobemide Overdose. <i>International Clinical Psychopharmacology</i> , 1988, 3, 325-326.	1.7	10
121	High-affinity platelet [3H]LSD binding is decreased in panic disorder. <i>Journal of Affective Disorders</i> , 1990, 19, 119-123.	4.1	10
122	Evidence for 5-HT _{1A} receptor control of pineal melatonin concentrations in the rat. <i>European Neuropsychopharmacology</i> , 1998, 8, 183-186.	0.7	10
123	Effect of the menstrual cycle stage on the melatonin suppression by dim white light. <i>Psychoneuroendocrinology</i> , 1999, 24, 193-200.	2.7	10
124	Nefazodone in the Breast Milk of Nursing Mothers: A Report of Two Patients. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 717-718.	1.4	10
125	A CONTROLLED COMPARATIVE TRIAL OF CLORAZEPATE (TRANXENE) AND DIAZEPAM (VALIUM) FOR ANXIETY. <i>Medical Journal of Australia</i> , 1977, 2, 525-528.	1.7	9
126	Pharmacokinetic aspects of antidepressant treatment in the elderly. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1993, 17, 329-344.	4.8	9

#	ARTICLE	IF	CITATIONS
127	Olanzapine in Anorexia Nervosa. Australian and New Zealand Journal of Psychiatry, 2003, 37, 494-494.	2.3	9
128	Anxiety and the Benzodiazepine Receptor. Progress in Brain Research, 1986, 65, 73-90.	1.4	8
129	Plasma immunoreactive β -endorphin in dexamethasone suppressors and non-suppressors of cortisol. Journal of Affective Disorders, 1987, 12, 233-239.	4.1	8
130	The effect of stress on melatonin and serotonin in rat brain. Stress and Health, 1989, 5, 5-8.	0.5	8
131	A Short Term Open Clinical Trial of Clobazam in the Treatment of Patients with Panic Attacks. International Clinical Psychopharmacology, 1989, 4, 285-294.	1.7	8
132	Differential Diagnosis and Drug Treatment of Panic Disorder, Anxiety and Depression. CNS Drugs, 1994, 1, 119-131.	5.9	8
133	Plasma and human milk concentrations of moclobemide in nursing mothers. Human Psychopharmacology, 1998, 13, 579-582.	1.5	8
134	The effect of single oral doses of zopiclone on nocturnal melatonin secretion in healthy male volunteers. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2001, 25, 825-833.	4.8	8
135	The Emerging Role of Pharmacogenetics: Implications for Clinical Psychiatry. Australian and New Zealand Journal of Psychiatry, 2004, 38, 483-489.	2.3	8
136	A NEW ANTIDEPRESSANT BUTRIPTYLINE: PLASMA LEVELS AND CLINICAL RESPONSE. Medical Journal of Australia, 1977, 2, 604-606.	1.7	8
137	Plasma Nomifensine Concentration. International Pharmacopsychiatry, 1980, 15, 325-333.	0.4	7
138	Zimelidine: A placebo-controlled trial in depression. Psychiatry Research, 1983, 8, 95-103.	3.3	7
139	Plasma concentrations of benzodiazepines – A review of clinical findings and implications. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1984, 8, 115-126.	4.8	7
140	PLATELET MONOAMINE OXIDASE ACTIVITY IN PATIENTS WITH HUNTINGTON'S DISEASE. Clinical and Experimental Pharmacology and Physiology, 1987, 14, 547-550.	1.9	7
141	Pharmacotherapy of Panic Disorder. International Review of Psychiatry, 1990, 2, 399-409.	2.8	7
142	Melatonin sensitivity to dim white light in different seasons. Human Psychopharmacology, 1999, 14, 53-58.	1.5	7
143	An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers. Human Psychopharmacology, 2008, 23, 129-137.	1.5	7
144	One-Year Treatment Continuation in Patients Switched to Paliperidone Palmitate. Journal of Clinical Psychiatry, 2014, 75, 1267-1269.	2.2	7

#	ARTICLE	IF	CITATIONS
145	Melatonin in panic disorder. <i>Biological Psychiatry</i> , 1986, 21, 1438-1439.	1.3	6
146	A kinetic analysis of platelet monoamine oxidase activity in patients with panic attacks. <i>Journal of Affective Disorders</i> , 1988, 15, 127-130.	4.1	6
147	Subsensitive melatonin suppression by dim white light: possible biological marker of panic disorder. <i>International Journal of Neuropsychopharmacology</i> , 1998, 1, 115-120.	2.1	6
148	The effect of age and pre-light melatonin concentration on the melatonin sensitivity to dim light. <i>International Clinical Psychopharmacology</i> , 1999, 14, 189-192.	1.7	6
149	The neurobiology of benzodiazepine receptors in panic disorder and post-traumatic stress disorder. <i>Stress and Health</i> , 2008, 24, 13-21.	2.6	6
150	Ethnic differences in psychotropic drug response and pharmacokinetics. , 2008, , 38-61.		6
151	Desvenlafaxine in the treatment of major depression: an updated overview. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1087-1097.	1.8	6
152	Maprotiline in affective illness. <i>Journal of Affective Disorders</i> , 1983, 5, 147-154.	4.1	5
153	ANTIDEPRESSANTS: CLINICAL ASPECTS. <i>Stress and Health</i> , 1997, 13, 167-172.	0.5	5
154	Melatonin: hormone of the night. <i>Acta Neuropsychiatrica</i> , 2009, 21, 263-265.	2.1	5
155	Doxepin Plasma Levels and Anxiolytic Response. <i>International Pharmacopsychiatry</i> , 1980, 15, 247-252.	0.4	4
156	Plasma Prolactin and Fluphenazine Concentrations in Patients receiving Fluphenazine Decanoate: Stability over Injection Intervals. <i>International Clinical Psychopharmacology</i> , 1987, 2, 299-305.	1.7	4
157	Pharmacokinetic and Pharmacodynamic Effects of a Single Nocturnal Dose of Alprazolam. <i>International Clinical Psychopharmacology</i> , 1990, 5, 111-118.	1.7	4
158	Brain monoamines and early visual information-processing speed. <i>International Journal of Neuropsychopharmacology</i> , 2002, 5, 295-300.	2.1	4
159	Combination Antidepressants are not yet Proven Therapy in the Treatment of Depression. <i>Australasian Psychiatry</i> , 2007, 15, 248-249.	0.7	4
160	Dysfunctional Circadian Rhythms and Mood Disorders: Opportunities for Novel Therapeutic Approaches. <i>Modern Problems of Pharmacopsychiatry</i> , 2010, , 32-52.	2.5	4
161	The effect of agomelatine on 5HT _{2C} receptors in humans: a clinically relevant mechanism?. <i>Psychopharmacology</i> , 2012, 221, 177-178.	3.1	4
162	Liver Impairment Associated with Nomifensine. <i>Australian and New Zealand Journal of Psychiatry</i> , 1983, 17, 288-289.	2.3	3

#	ARTICLE	IF	CITATIONS
163	A Portable Light Source for Bright Light Treatment. <i>Sleep</i> , 1990, 13, 272-275.	1.1	3
164	Suicide, violent behaviour and fluoxetine. <i>Medical Journal of Australia</i> , 1994, 161, 404-405.	1.7	3
165	Contemporary Therapies for Depression in Older People. <i>Journal of Pharmacy Practice and Research</i> , 2010, 40, 58-64.	0.8	3
166	Agomelatine, melatonin and depressive disorder. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 407-410.	4.1	3
167	An open label trial of venlafaxine in war veterans with chronic post traumatic stress disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, A31-A31.	2.3	3
168	Who bears the costs of antidepressants in Australia?. <i>Medical Journal of Australia</i> , 1995, 162, 162-162.	1.7	3
169	Treatment of Seasonal Affective Disorder with Light: Preliminary Australian Experience. <i>Australian and New Zealand Journal of Psychiatry</i> , 1989, 23, 369-372.	2.3	2
170	Buspirone and Fluoxetine in the Treatment of OCD. <i>Australian and New Zealand Journal of Psychiatry</i> , 1992, 26, 684-686.	2.3	2
171	Stress and isatin: Effects on the serotonergic system. <i>Stress and Health</i> , 1992, 8, 141-145.	0.5	2
172	Platelet [3H]-paroxetine binding in obsessive-compulsive disorder. <i>Human Psychopharmacology</i> , 1995, 10, 141-146.	1.5	2
173	Stress induced animal models of depression. <i>Stress and Health</i> , 2000, 16, 195-197.	0.5	2
174	Agomelatine, Melatonin and Depression. , 2016, , 229-247.		2
175	Diagnostic agreement and concordance between consultation-liaison psychiatry and non-psychiatric (medical and surgical) doctors: changes within junior doctor's terms. <i>Australasian Psychiatry</i> , 2022, 30, 60-63.	0.7	2
176	Plasma fluphenazine concentrations in outpatients receiving fluphenazine decanoate (Modecate). <i>Human Psychopharmacology</i> , 1986, 1, 89-92.	1.5	1
177	Urinary Tribulin Output in Patients with Panic Attacks. <i>British Journal of Psychiatry</i> , 1988, 152, 295-296.	2.8	1
178	Long-term management of depressive disorders. <i>Current Therapeutic Research</i> , 1993, 54, 832-837.	1.2	1
179	The Test Re-Test Reliability of the Melatonin Suppression by White Light. <i>Biological Rhythm Research</i> , 1999, 30, 467-475.	0.9	1
180	Mechanism of action of mirtazapine: dual action or dual effect?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2004, 38, 267-269.	2.3	1

#	ARTICLE	IF	CITATIONS
181	Pharmacotherapy for Mood and Anxiety Disorders. Mental Health and Illness Worldwide, 2017, , 427-453.	0.1	1
182	Presence of olanzapine in breast milk. Australian and New Zealand Journal of Psychiatry, 2000, 34, A16-A16.	2.3	1
183	Fluoxetine â€” Delayed halfâ€”life and an Adverse Event. Medical Journal of Australia, 1993, 158, 722-723.	1.7	1
184	Monitoring and Interpretation of Antidepressant Plasma Concentrations. Australian and New Zealand Journal of Psychiatry, 1982, 16, 74-78.	2.3	0
185	Platelet monoamine uptake in depression ? primary or secondary phenomenon?. Human Psychopharmacology, 1987, 2, 47-47.	1.5	0
186	Platelet serotonin response to treatment in geriatric depression. Biological Psychiatry, 1989, 26, 434-436.	1.3	0
187	Platelet MAO and 5â€”HT uptake in agoraphobics. British Journal of Psychiatry, 1990, 156, 592-593.	2.8	0
188	Guest Editorial: International Society for the Investigation of Stress (ISIS). Stress and Health, 2002, 18, 59-60.	2.6	0
189	Mechanism of Action of Mirtazapine: Dual Action or Dual Effect?. Australian and New Zealand Journal of Psychiatry, 2004, 38, 267-269.	2.3	0
190	Fifth World Congress on Stress, London, 18â€”19 June 2004. Stress and Health, 2004, 20, 173-174.	2.6	0
191	Human Embryonic Stem Cells: A Resource for In Vitro Neuroscience Research?. Neuropsychopharmacology, 2006, 31, 2571-2572.	5.4	0
192	How does your garden growâ€”therapeutic principles from herbal remedies?. Stress and Health, 2008, 24, 1-2.	2.6	0
193	Duloxetine in the acute and continuation treatment of major depressive disorder. Expert Review of Neurotherapeutics, 2011, 11, 1525-1539.	2.8	0
194	The Decline and Fall of the Psychopharmacology Empire?. Australian and New Zealand Journal of Psychiatry, 2011, 45, 1005-1005.	2.3	0
195	Problematic medical marijuana, but not all cannabinoids?. Australian and New Zealand Journal of Psychiatry, 2018, 52, 95-95.	2.3	0
196	Agomelatine: Profile and applications to depression. , 2021, , 301-308.		0
197	A positron emission tomography study of benzodiazepine receptors in post-traumatic stress disorder. Australian and New Zealand Journal of Psychiatry, 2000, 34, A21-A21.	2.3	0
198	Mechanisms underlying the speed of onset of antidepressant response. , 2001, , 47-61.		0

#	ARTICLE	IF	CITATIONS
199	Antidepressant Drug Measurement: Review of Methods for Clinical Application. , 1989, , 605-610.		0
200	Pharmacotherapy for Mood and Anxiety Disorders. Mental Health and Illness Worldwide, 2016, , 1-27.	0.1	0
201	Clinical evaluation of the cardiac effects of new psychotropic drugs. , 1983, , 83-98.		0
202	Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics?. Australian and New Zealand Journal of Psychiatry, 2005, 39, 146-153.	2.3	0